Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MMP9 | P14780 | 7/20 | 0.64 |
| ▸ | MMP2 | P08253 | 8/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252463 | 1.00 | TDP1 (0.79) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| SCHEMBL8063645 | 0.89 | TDP1 (0.78) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| SCHEMBL1203540 | 0.89 | MMP2 (0.79) | TDP1MMP9MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL697477 | 0.89 | MMP2 (0.79) | TDP1MMP9MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL697476 | 0.89 | MMP2 (0.79) | TDP1MMP9MMP2ADAMTS4ALDH1A1 | |
| SCHEMBL8817150 | 0.88 | TDP1 (0.77) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| SCHEMBL8650150 | 0.88 | TDP1 (0.77) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| SCHEMBL8817154 | 0.88 | TDP1 (0.77) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| SCHEMBL8387442 | 0.88 | TDP1 (0.77) | TDP1L3MBTL1MEN1KMT2AMMP9 | |
| Hydrochloric Acid SCHEMBL3839410 | 0.88 | MMP2 (0.77) | TDP1MMP9MMP2ADAMTS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522611-B2 | Process for the preparation of high pure Eribulin and its Mesylate salt | NATCO PHARMA LIMITED (IN) | 2026-01-13 | — | — | US | disclosed |
| US-20220089607-A1 | PROCESS FOR THE PREPARATION OF HIGH PURE ERIBULIN AND ITS MESYLATE SALT | NATCO PHARMA LIMITED (IN) | 2022-03-24 | — | — | US | disclosed |
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2009-12-24 | — | — | US | disclosed |
| WO-2008022462-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | UNIVERSITY OF NORTHERN BRITISH COLUMBIA (CA) | 2008-02-28 | — | — | WO | disclosed |
| EP-1377542-B1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | AMBRILIA BIOPHARMA INC (CA) | 2007-08-01 | — | — | EP | disclosed |
| EP-1803706-A1 | HIV protease inhibitors based on amino acid derivatives | Ambrilia Biopharma Inc. (CA) | 2007-07-04 | — | — | EP | disclosed |
| WO-2005057589-A2 | MULTI-PURPOSE AUTOMATED RADIOTRACER SYNTHESIZER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-06-23 | — | — | WO | disclosed |
| US-6677367-B2 | LYSINE DERIVATIVE WITH 2-AMINOSULFONYLTHIOPHENE SUBSTITUENT; ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) VIRICIDES | PHARMACOR INC. (CA) | 2004-01-13 | — | — | US | disclosed |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-10-16 | — | — | US | disclosed |
| US-6610689-B2 | Viricides | PHARMACOR INC. (CA) | 2003-08-26 | — | — | US | disclosed |
| US-6608100-B1 | N-epsilon-amino acid substituted L-lysine sulfonamide derivatives possessing aspartyl protease inhibitory properties | PHARMACOR INC. (CA) | 2003-08-19 | — | — | US | disclosed |
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-07-31 | — | — | US | disclosed |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2003-06-26 | — | — | US | disclosed |
| US-6506786-B2 | Such as N-isobutyl-N-(4-methylbenzene-sulfonyl)-N-(N-(4-methylbenzenesulfonyl)-L -phenylalanyl)-L-lysine | PHARMACOR INC. (CA) | 2003-01-14 | — | — | US | disclosed |
| EP-1255531-A1 | TANNING PREPARATION FOR THE SKIN | Dija Zeist B.V. (NL) | 2002-11-13 | — | — | EP | disclosed |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | TAIMED BIOLOGICS, INC. (TW) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064551-A1 | HIV PROTEASE INHIBITORS BASED ON AMINO ACID DERIVATIVES | PHARMACOR INC. (CA) | 2002-08-22 | — | — | WO | disclosed |
| WO-2001060330-A1 | TANNING PREPARATION FOR THE SKIN | DIJA ZEIST B.V. (NL) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144265-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | TDP1 3179/4885L3MBTL1 2747/4885MEN1 4422/4885 |
| US-20220089607-A1 | PROCESS FOR THE PREPARATION OF HIGH PURE ERIBULIN AND ITS MESYLATE SALT | ERLIN1, ERLIN2, ERGIC1 | TDP1 4667/4885L3MBTL1 4872/4885MEN1 756/4885 |
| US-20020151546-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | TDP1 3179/4885L3MBTL1 2747/4885MEN1 4422/4885 |
| US-20030195159-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | TDP1 3179/4885L3MBTL1 2747/4885MEN1 4422/4885 |
| US-20090318548-A1 | PARA-QUINOL DERIVATIVES AND METHODS OF STEREO SELECTIVELY SYNTHESIZING AND USING SAME | CBR3, XDH, NQO2 | TDP1 1801/4885L3MBTL1 3540/4885MEN1 3482/4885 |
| US-20030119803-A1 | HIV protease inhibitors based on amino acid derivatives | ANPEP, PEPD, XPNPEP1 | TDP1 3179/4885L3MBTL1 2747/4885MEN1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.